Brief: AB Science: Independent Publication Sees Masitinib As Possible Alzheimer's Therapy
08/03/2021 07:21
March 8 (Reuters) - AB Science SA ABS.PA :
* AB SCIENCE ANNOUNCES THAT A NEW INDEPENDENT PUBLICATION
CONFIRMS
THE ROLE OF MASITINIB AS A POTENTIAL THERAPY IN
NEURODEGENERATIVE DISORDERS INCLUDING ALZHEIMER'S DISEASE
Source text: https://bit.ly/3bqeu8r
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on AB Science SA
See all newsBrief: AB Science Expects To Resume AB8939 Phase 1 In Q1 2027 And Masitinib Phase 3 In Q4 2027
Brief: AB Science Discontinues Phase 2 AB20006, Phase 3 AB15003, Phase 3 AB20009 Studies
Brief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041